The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence
Author
Abstract
Suggested Citation
Download full text from publisher
Other versions of this item:
- Hostenkamp, Gisela & Lichtenberg, Frank R., 2015. "The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence," Social Science & Medicine, Elsevier, vol. 130(C), pages 162-171.
References listed on IDEAS
- Lichtenberg Frank R., 2010. "Pharmaceutical Price Discrimination and Social Welfare," Capitalism and Society, De Gruyter, vol. 5(1), pages 1-32, July.
- Joseph E. Aldy & W. Kip Viscusi, 2008.
"Adjusting the Value of a Statistical Life for Age and Cohort Effects,"
The Review of Economics and Statistics, MIT Press, vol. 90(3), pages 573-581, August.
- Aldy, Joseph E. & Viscusi, W. Kip, 2006. "Adjusting the Value of a Statistical Life for Age and Cohort Effects," RFF Working Paper Series dp-06-19, Resources for the Future.
- Lichtenberg Frank R., 2010.
"Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia,"
Forum for Health Economics & Policy, De Gruyter, vol. 13(2), pages 1-18, August.
- Frank R. Lichtenberg, 2010. "Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia," NBER Working Papers 16051, National Bureau of Economic Research, Inc.
- Lichtenberg, Frank R., 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009," Economics & Human Biology, Elsevier, vol. 13(C), pages 107-127.
- Lichtenberg Frank R., 2013.
"The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files,"
Forum for Health Economics & Policy, De Gruyter, vol. 16(1), pages 1-33, January.
- Frank R. Lichtenberg, 2012. "The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files," NBER Working Papers 18552, National Bureau of Economic Research, Inc.
- Lichtenberg, Frank R., 2013.
"The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007,"
Social Science & Medicine, Elsevier, vol. 77(C), pages 50-59.
- Frank R. Lichtenberg, 2011. "The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007," NBER Working Papers 17414, National Bureau of Economic Research, Inc.
- Olson, Mary K., 2008. "The risk we bear: The effects of review speed and industry user fees on new drug safety," Journal of Health Economics, Elsevier, vol. 27(2), pages 175-200, March.
- Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Frank R. Lichtenberg, 2015.
"Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010,"
International Journal of the Economics of Business, Taylor & Francis Journals, vol. 22(2), pages 277-299, July.
- Frank Lichtenberg, 2015. "Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010," CESifo Working Paper Series 5166, CESifo.
- Lichtenberg, Frank R., 2014. "The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009," Economics & Human Biology, Elsevier, vol. 13(C), pages 107-127.
- Frank R. Lichtenberg & Billie Pettersson, 2014.
"The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data,"
Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 23(3), pages 239-273, April.
- Frank Lichtenberg & Billie Pettersson, 2012. "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data," CESifo Working Paper Series 3894, CESifo.
- Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
- Nishimura, Junichi & Nagaoka, Sadao & Yoneyama-Hirozane, Mariko, 2022. "The impact of science-intensive drugs on longevity and cure rate: Evidence from new prescription drugs launched in Japan," Journal of the Japanese and International Economies, Elsevier, vol. 64(C).
- Nemanja Rancic & Mihajlo (Michael) Jakovljevic, 2016. "Long Term Health Spending Alongside Population Aging in N-11 Emerging Nations," Eastern European Business and Economics Journal, Eastern European Business and Economics Studies Centre, vol. 2(1), pages 2-26.
- Ryan Edwards, 2013.
"The cost of uncertain life span,"
Journal of Population Economics, Springer;European Society for Population Economics, vol. 26(4), pages 1485-1522, October.
- Ryan D. Edwards, 2008. "The Cost of Uncertain Life Span," NBER Working Papers 14093, National Bureau of Economic Research, Inc.
- James K. Hammitt, 2020.
"Valuing mortality risk in the time of COVID-19,"
Journal of Risk and Uncertainty, Springer, vol. 61(2), pages 129-154, October.
- Hammitt, James K., 2020. "Valuing mortality risk in the time of covid-19," TSE Working Papers 20-1115, Toulouse School of Economics (TSE).
- Moreno Gigi & van Eijndhoven Emma & Benner Jennifer & Sullivan Jeffrey, 2017. "The Long-Term Impact of Price Controls in Medicare Part D," Forum for Health Economics & Policy, De Gruyter, vol. 20(2), pages 1-56, December.
- Kuhn, Michael & Frankovic, Ivan & Wrzaczek, Stefan, 2017.
"Medical Progress, Demand for Health Care, and Economic Performance,"
VfS Annual Conference 2017 (Vienna): Alternative Structures for Money and Banking
168249, Verein für Socialpolitik / German Economic Association.
- Frankovic, Ivan & Kuhn, Michael & Wrzaczek, Stefan, 2017. "Medical progress, demand for health care, and economic performance," ECON WPS - Working Papers in Economic Theory and Policy 08/2017, TU Wien, Institute of Statistics and Mathematical Methods in Economics, Economics Research Unit.
- Anna Scherbina, 2021. "Assessing the Optimality of a COVID Lockdown in the United States," Economics of Disasters and Climate Change, Springer, vol. 5(2), pages 177-201, July.
- Daniel Tobias Michaeli & Thomas Michaeli & Sebastian Albers & Tobias Boch & Julia Caroline Michaeli, 2024. "Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 979-997, August.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Zahran, Sammy & Iverson, Terrence & McElmurry, Shawn P. & Weiler, Stephan & Levitt, Ryan, 2019. "Hidden Costs of Blight and Arson in Detroit: Evidence From a Natural Experiment in Devil's Night," Ecological Economics, Elsevier, vol. 157(C), pages 266-277.
- Martin Gaynor & Nirav Mehta & Seth Richards-Shubik, 2023. "Optimal Contracting with Altruistic Agents: Medicare Payments for Dialysis Drugs," American Economic Review, American Economic Association, vol. 113(6), pages 1530-1571, June.
- Spyros Arvanitis & Euripidis N. Loukis, 2014. "Investigating the effects of ICT on innovation and performance of European hospitals," KOF Working papers 14-366, KOF Swiss Economic Institute, ETH Zurich.
- Aldy, Joseph, 2019. "Birds of a Feather: Estimating the Value of Statistical Life from Dual-Earner Families," Working Paper Series rwp19-013, Harvard University, John F. Kennedy School of Government.
- Herrera-Araujo, Daniel & Rochaix, Lise, 2020.
"Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France,"
Journal of Environmental Economics and Management, Elsevier, vol. 103(C).
- Daniel Herrera Araujo & Lise Rochaix, 2020. "Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France," Post-Print hal-03353422, HAL.
- Daniel Herrera Araujo & Lise Rochaix, 2020. "Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France," PSE-Ecole d'économie de Paris (Postprint) hal-03353422, HAL.
- Patrick Carlin & Brian E. Dixon & Kosali I. Simon & Ryan Sullivan & Coady Wing, 2022. "How Undervalued is the Covid-19 Vaccine? Evidence from Discrete Choice Experiments and VSL Benchmarks," NBER Working Papers 30118, National Bureau of Economic Research, Inc.
- Antoine Bommier & Bertrand Villeneuve, 2012.
"Risk Aversion and the Value of Risk to Life,"
Journal of Risk & Insurance, The American Risk and Insurance Association, vol. 79(1), pages 77-104, March.
- Antoine Bommier & Bertrand Villeneuve, 2004. "Risk Aversion and the Value of Risk to Life," CESifo Working Paper Series 1267, CESifo.
- Antoine Bommier & Bertrand Villeneuve, 2010. "Risk Aversion and the Value of Risk to Life," CER-ETH Economics working paper series 10/133, CER-ETH - Center of Economic Research (CER-ETH) at ETH Zurich.
- Antoine Bommier & Bertrand Villeneuve, 2012. "Risk Aversion and the Value of Risk to Life," Post-Print hal-01685924, HAL.
- Bommier, Antoine & Villeneuve, Bertrand, 2008. "Risk Aversion and the Value of Risk to Life," MPRA Paper 11943, University Library of Munich, Germany.
More about this item
JEL classification:
- I12 - Health, Education, and Welfare - - Health - - - Health Behavior
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
- O33 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Technological Change: Choices and Consequences; Diffusion Processes
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ces:ceswps:_4516. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Klaus Wohlrabe (email available below). General contact details of provider: https://edirc.repec.org/data/cesifde.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.